NIV Discovers Anti-Viral Breakthrough Against Chandipura Virus Threat

A major step in the direction of infectious disease research in India, Pune-based National Institute of Virology (NIV), under the Indian Council of Medical Research (ICMR), has found anti-viral drug Favipiravir as a potential candidate against Chandipura virus (CHPV). The finding provides a ray of hope in control of this deadly encephalitis-causing virus, that is majorly prevalent in children and endemic in central parts of India.

Preclinical studies conducted on mice have shown that Favipiravir reduces viral load and improves survival rates, according to Dr Naveen Kumar, Director of NIV. “The NIV has been working toward identifying potential anti-virals against CHPV. In the search after testing multiple anti-virals, Favipiravir has been identified to give substantial protection against the Chandipura virus infection which has also been established in the preclinical trials in the laboratory,” he said.

Leader's Thoughts: Anti-Infectives: How New Research is Shaping Infection Control

CHPV, a member of the Rhabdoviridae family, was first isolated in Maharashtra in 1965. It has since caused outbreaks with alarmingly high fatality rates, notably in 2003 and again in 2024, when Gujarat and parts of Maharashtra reported 64 confirmed cases, primarily among children.

While symptomatic treatment remains the only available option, clinical trials on humans for Favipiravir are expected following additional animal efficacy tests at ICMR-National Animal Research Facility. Besides that, vaccine research has been begun by NIV to produce long-term protection. Experts emphasize the necessity of proper control, hygiene, and public awareness to prevent the spread.